Cassava Sciences ( SAVA ) Reports FY22 Results , Provides Operating Update
The company behind Simufilam has announced financial results for the year ended December 31, 2022, and says it expects to reach a target of thousands of patients in phase three clinical studies in Alzheimer’s disease dementia studies, according to the company.
Source: streetinsider.comPublished on 2023-02-28
Related news
- These Are the Riskiest Smart City Technologies , Cybersecurity Experts Say
- Cassava Sciences Reports Second Quarter Financial Results for 2022 , Mid - year Corporate Update and Interim Analysis of Open - label Study
- How to Use the Analyze Data Feature in Microsoft Excel
- Cyber Security Today , May 10 , 2021 – Deadline looms for Women In Cyber Day petition , data theft from insurance quote websites and advice from Canada top cyber agency
- Lingokids is looking for highly qualified talent to reinforce its international growth
- Cassava Sciences Reports Full - year 2022 Financial Results and Operating Updates
- Police recorded crime and outcomes open data tables
- Four constraints for adoption of electronic data collection methods